Northbank Heralds Successful IPO of its Client AMT on the Euronext Amsterdam Exchange

London, Manchester, Munich – 28th June 2007  Northbank Communications announced the first day of trading on 20th June for its client, Amsterdam Molecular Therapeutics (AMT), that is active in the field of human gene therapy. AMT successfully listed on Amsterdam's Eurolist by Euronext, raising €50 million before expenses. The offering comprised 5 million shares, excluding a 750,000 over-allotment, and was priced at €10 per share, the top end of the range. At the start of trading, the company had a market capitalisation of €139 million. At the end of the first day's trading, the share price closed unchanged at €10. [EURONEXT: AMT]

AMT intends to use the proceeds from its IPO primarily for the development and commercialisation of its products. It also plans to build a specialist team capable of marketing and selling its lead product, AMT-011, in Europe and North America. One of AMT's six pipeline products, AMT-011 is designed to treat LPL deficiency and is currently in pre-registration clinical trials.

Northbank has provided PR counsel to AMT since October 2006, developing the Company's messages in preparation for the IPO.

Commenting on the IPO, Sue Charles, CEO of Northbank said:

"We are delighted to have worked alongside AMT through its Euronext IPO, and look forward to supporting the Company's communications as a publicly-traded business."

Currently representing 22 listed and 60 private companies, Northbank has specialist experience of corporate, financial and marketing communications in the life science sector. It also previously supported clients through IPOs on London's AIM and on the Copenhagen Exchange, and listings by reverse take over on AIM and NASDAQ.

In the months leading up to the IPO, Northbank worked with AMT to distribute and support seven news announcements, achieving over 60 articles in a wide range of publications including: global wires (Dow Jones, Reuters, AFX, Bloomberg, Betten), business press (BioCentury, BioWorld, Scrip), and national publications (Het Financieele Dagblad, NRC Handelsblad, The Times (of London), l'Agefi).

Adam Michael, Account Director, leading the team on the AMT account said:

"At the beginning of the programme, Northbank briefed key media on AMT, the potential of its science and technology, and the company's lead products. We helped copywrite press releases, and planned media interviews to complement the roadshow. All these activities were done in coordination with the in-house communications team, plus the legal and banking teams. Throughout the programme, Northbank was on hand around the clock to ensure rapid response media relations, consultancy and press release distribution."

© 2007 College Hill Associates | Registered in England No 1036926 / VAT No 245666930 | Legal